We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+8.01%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$20.1B
AUM Growth
+$3.5B
Cap. Flow
+$2.5B
Cap. Flow %
12.41%
Top 10 Hldgs %
33.13%
Holding
257
New
120
Increased
40
Reduced
39
Closed
20

Top Sells

Rank Stock Value
1
TIF
Tiffany & Co.
TIF
+$301M
2
NYT icon
New York Times
NYT
+$209M
3
V icon
Visa
V
+$194M
4
ELV icon
Elevance Health
ELV
+$145M
5
ABBV icon
AbbVie
ABBV
+$123M

Sector Composition

Rank Sector Weight
1 Healthcare 35.71%
2 Technology 14.95%
3 Financials 13.65%
4 Communication Services 11.15%
5 Industrials 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WPCB.U
151
DELISTED
Warburg Pincus Capital Corporation I-B Units, each consisting of one Class A ordinary share, and one-fifth of one redeemable warrant
WPCB.U
$7.49M 0.04%
+750,000
New +$7.55M
GSEVU
152
DELISTED
Gores Holdings VII, Inc. Units
GSEVU
$7.47M 0.04%
+750,000
New +$7.64M
SLACU
153
DELISTED
Social Leverage Acquisition Corp I Units, each consisting of one share of Class A common stock and one-fourth of one redeemable warrant
SLACU
$7.46M 0.04%
+750,000
New +$7.74M
VAQC
154
DELISTED
Vector Acquisition Corporation II Class A Ordinary Shares
VAQC
$7.42M 0.04%
+750,000
New +$7.47M
PFDRU
155
DELISTED
Pathfinder Acquisition Corporation Unit
PFDRU
$7.42M 0.04%
+750,000
New +$7.62M
TBCPU
156
DELISTED
Thunder Bridge Capital Partners III Inc. Units
TBCPU
$7.42M 0.04%
+750,000
New +$7.67M
CNTB
157
Connect Biopharma Holdings
CNTB
$149M
$7.4M 0.04%
+400,000
New +$6.81M
STRE.U
158
DELISTED
Supernova Partners Acquisition Company III, Ltd. Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant
STRE.U
$7M 0.03%
+700,000
New +$6.98M
NXU.U
159
DELISTED
Novus Capital Corporation II Units, each consisting of one share of Class A common stock and one thi
NXU.U
$7M 0.03%
+700,000
New +$7.31M
FNCH
160
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$6.21M 0.03%
+13,000
New +$6.62M
IMGN
161
DELISTED
Immunogen Inc
IMGN
$6.08M 0.03%
750,000
-250,000
-25% -$2.04M
KVSA
162
DELISTED
Khosla Ventures Acquisition Co. Class A Common Stock
KVSA
$6.06M 0.03%
+600,000
New +$6.17M
GTPBU
163
DELISTED
Gores Technology Partners II, Inc. Units
GTPBU
$5.98M 0.03%
+600,000
New +$6.07M
FSRXU
164
DELISTED
FinServ Acquisition Corp. II Unit
FSRXU
$5.98M 0.03%
+600,000
New +$6.21M
IPVIU
165
DELISTED
InterPrivate IV InfraTech Partners Inc. Units
IPVIU
$5.93M 0.03%
+600,000
New +$5.98M
RXRAU
166
DELISTED
RXR Acquisition Corp. Units
RXRAU
$5.91M 0.03%
+600,000
New +$5.96M
PHVS icon
167
Pharvaris
PHVS
$2.55B
$5.61M 0.03%
+200,000
New +$6.29M
COGT icon
168
Cogent Biosciences
COGT
$6.37B
$5.27M 0.03%
600,000
HARP
169
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$5.23M 0.03%
+25,000
New +$5.01M
TBA
170
DELISTED
Thoma Bravo Advantage
TBA
$5.22M 0.03%
+500,000
New +$5.79M
CGEM icon
171
Cullinan Oncology
CGEM
$1.4B
$5.21M 0.03%
+125,000
New +$5.07M
INNV icon
172
InnovAge Holding
INNV
$1.49B
$5.16M 0.03%
+200,000
New +$4.93M
SRNGU
173
DELISTED
Soaring Eagle Acquisition Corp. Unit
SRNGU
$5.06M 0.03%
+500,000
New +$5.21M
AUS.U
174
DELISTED
Austerlitz Acquisition Corporation I Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
AUS.U
$5.02M 0.02%
+500,000
New +$5.08M
SMRT icon
175
SmartRent
SMRT
$274M
$5M 0.02%
+500,000
New +$5.27M

Similar funds

Thomas Steyer's Q1 2021 Portfolio in Review

As of Q1 2021, Thomas Steyer held 257 positions worth $20.1B, up 21% from $16.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Thomas Steyer deployed $2.5B of net new capital in Q1 2021, opening 120 new positions and adding to 40 existing holdings. Its largest new stake was Mastercard: 985,920 shares worth $351M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was New York Times, an estimated $209M trimmed.

  • Thomas Steyer's largest Q1 2021 buy was Mastercard: 985,920 shares worth $351M.
  • Thomas Steyer added most to Alexion Pharmaceuticals in Q1 2021, an estimated $546M increase.
  • Thomas Steyer's biggest Q1 2021 reduction was New York Times, cutting an estimated $209M.
  • Thomas Steyer fully exited Tiffany & Co. in Q1 2021, selling an estimated $301M.
  • Thomas Steyer's ten largest holdings make up 33% of its $20.1B portfolio in Q1 2021.
  • Thomas Steyer opened 120 new positions and closed 20 in Q1 2021.
  • Thomas Steyer's portfolio value rose 21% quarter-over-quarter to $20.1B.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.